Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy

NCT07021976 is registered in ClinicalTrials.gov with Shandong Suncadia Medicine Co., Ltd. as lead sponsor.

NCT NCT07021976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07021976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy
Lead sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 11, 2025
Completion date
November 30, 2026
Enrollment
228 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obstructive hypertrophic cardiomyopathy